Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by bilosellhion Mar 31, 2005 4:58pm

181 Views

Post# 8841860

RE: bilo

one further point to add re: BIOEYE's reappearance just before the Feb/04 onc news release re: UK ph I systemic trials. about a month later in March, onc announced a $6.7M Cdn pp with a European investor at $6.25, which happened to close Apr 8, curiously coinciding exactly with BIOEYE's retreat from the boards... also interesting is that nowhere in onc's news releases announcing the financing or its closing, is the adviser's name mentioned - the one who received 7% commission plus 107K $7.00 Cdn warrants that expire in Oct/05, unlike its other financing announcements where onc specifically names cannacord.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading